Dapagliflozin – do we need it registered for type 2 diabetes?

Link to article at PubMed

Related Articles

Dapagliflozin - do we need it registered for type 2 diabetes?

Expert Opin Pharmacother. 2014 Jul 5;:1-5

Authors: Doggrell SA, Tuli R

Introduction: Inhibitors of the sodium-glucose co-transporter 2 (SGLT2) promote the excretion of glucose to reduce glycated hemoglobin (HbA1c) levels. Canagliflozin was the first SGLT2 inhibitor to be approved by the US FDA for use in the treatment of type 2 diabetes, and recently dapagliflozin has also been approved. Areas covered: We evaluated a recent Phase III clinical trial with dapagliflozin. Expert opinion: Dapagliflozin was studied as add-on therapy to sitagliptin with or without metformin, and was shown to lower HbA1c levels and body weight. The incidence of hypoglycaemia was low with dapagliflozin, but it did increase the incidence of urogenital infections. As no clear benefits have been identified for dapagliflozin over canagliflozin, which was the first gliflozin registered by the FDA, we do not fully understand why it was necessary to register dapagliflozin. Given that there are no completed cardiovascular/clinical outcome studies with dapagliflozin, and therefore no evidence of beneficial effect, it also seems premature to be using it extensively or considering it as an alternative to the clinically proven metformin.

PMID: 24998153 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published. Required fields are marked *